Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Allay Therapeutics

Allay Therapeutics Announces $57.5M Series D Financing and Venture Debt Line to Advance ATX101 and its Ultra-Sustained Pain Platform for Post-Surgical Pain Management
From Allay Therapeutics
Via Business Wire
Allay Therapeutics Announces First Patients Dosed in Pivotal Phase 2b Registration Trial of ATX101 for Post-Surgical Pain Management After Knee Replacement Surgery
From Allay Therapeutics
Via Business Wire
Allay Therapeutics Receives FDA Breakthrough Therapy Designation (BTD) for ATX101 for the Treatment of Post-surgical Pain Following Total Knee Replacement Surgery
From Allay Therapeutics
Via Business Wire
Allay Therapeutics Announces Expansion of Clinical and Scientific Advisory Boards to Support the Company’s Mission to Transform Post-Surgical Pain Management
From Allay Therapeutics
Via Business Wire
Allay Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application to Initiate Pivotal Phase 2B Trial of ATX101 for the Treatment of Post-Surgical Pain Following Total Knee Replacement Surgery
From Allay Therapeutics
Via Business Wire
Allay Therapeutics’ Phase 2B Clinical Study Supports Ability of ATX101 To Deliver Four Weeks of Sustained Post-surgical Pain Relief
From Allay Therapeutics
Via Business Wire
Allay Therapeutics Appoints Nicole Vitullo to Board of Directors
From Allay Therapeutics
Via Business Wire
No Opioids After Surgery: Evonik Invests in Allay Therapeutics and Supplies Key Technology for Pain Therapy Implants
From Allay Therapeutics
Via Business Wire
Allay Therapeutics Appoints Ron Burch, M.D., Ph.D. to Scientific Advisory Board
From Allay Therapeutics
Via Business Wire
Allay Therapeutics Establishes Corporate Headquarters in the Bay Area and Expands Base of Operations in Singapore
From Allay Therapeutics
Via Business Wire
Allay Therapeutics Completes Oversubscribed $60M Financing to Advance Ultra-Sustained Pain Platform
From Allay Therapeutics
Via Business Wire
Allay Therapeutics Appoints David Hewitt, M.D. as Chief Medical Officer
From Allay Therapeutics
Via Business Wire
Allay Therapeutics Launches with First Clinical Data to Demonstrate Weeks of Pain Relief with Ultra-Sustained Non-Opioid Platform
From Allay Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.